Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  International Journal of Oncology

• Publication date

  2004-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3892/IJO.25.5.1397PMID 15492831
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence

  2004cited by this paper
• Prediction of hormone sensitivity by DNA microarray.

  2004cited by this paper
• Tumor Markers

  2003cited by this paper
• Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.

  2003cited by this paper
• Clinical applications of proteomics.

  2003cited by this paper
• Exploiting the hallmarks of cancer: the future conquest of breast cancer.

  2003cited by this paper
• Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

  2003cited by this paper
• The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones

  2003cited by this paper
• Target discovery

  2003cited by this paper
• Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer.

  2003cited by this paper
• Gene expression profiles of primary breast tumors maintained in distant metastases

  2003cited by this paper
• Advanced statistical methods for the definition of new staging models.

  2003cited by this paper
• Pharmacogenetics goes genomic

  2003cited by this paper
• Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data

  2003cited by this paper
• Advantages and limitations of microarray technology in human cancer

  2003cited by this paper
• Tissue microarray study for classification of breast tumors.

  2003cited by this paper
• Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.

  2003cited by this paper
• Expanded Human Tissue Kallikrein Family – A Novel Panel of Cancer Biomarkers

  2002cited by this paper
• Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays

  2002cited by this paper
• Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.

  2002cited by this paper
• Apoptosis-based therapies

  2002cited by this paper
• Apoptosis A Link between Cancer Genetics and Chemotherapy

  2002cited by this paper
• Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

  2002cited by this paper
• Predictive molecular pathology.

  2002cited by this paper
• Clinical Proteomics for Cancer Biomarker Discovery and Therapeutic Targeting

  2002cited by this paper
• Pharmacogenomic biomarkers.

  2002cited by this paper
• Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

  2002cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• Human tissue kallikreins: a family of new cancer biomarkers.

  2002cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• The Expanded Human Kallikrein (KLK) Gene Family: Genomic Organisation, Tissue-Specific Expression and Potential Functions

  2001cited by this paper
• Prognostic Factors in Breast Cancer: Current and New Predictors of Metastasis

  2001cited by this paper
• Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

  2001cited by this paper
• Do we need prognostic factors in nodal-negative breast cancer? Arbiter.

  2000cited by this paper
• Twenty years of experience with the steroid receptor external quality assessment program - the paradigm for tumour biomarker EQA studies. On behalf of the EROTC Receptor and Biomarker Study Group.

  2000cited by this paper
• EORTC receptor and biomarker study group report analytical and technical evaluation of a thymidine kinase radio-enzymatic assay in breast cancer cytosols.

  2000cited by this paper
• Do we need better prognostic factors in node-negative breast cancer? Pro:.

  2000cited by this paper
• The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.

  2000cited by this paper
• EORTC Receptor and Biomarker Study Group Report: A Sandwich Enzyme-Linked Immunosorbent Assay for Vascular Endothelial Growth Factor in Blood and Tumor Tissue Extracts

  2000cited by this paper
• EORTC External Quality Assurance Program for ER and PgR Measurements: Trial 1998/1999

  2000cited by this paper
• Dissemination risk index based on plasminogen activator system components in primary breast cancer.

  1999cited by this paper
• Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.

  1998cited by this paper
• Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.

  1998cited by this paper
• External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.

  1998cited by this paper
• The urokinase‐type plasminogen activator system in cancer metastasis: A review

  1997cited by this paper
• Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy

  1997cited by this paper
• Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop.

  1996cited by this paper
• Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

  1996cited by this paper
• Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.

  1995cited by this paper
• Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.

  1994cited by this paper
• Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer

  1991cited by this paper
• Breast cancer prognostic factors: evaluation guidelines.

  1991cited by this paper
• Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

  1990cited by this paper
• Urokinase-type plasminogen activator antigen and early relapse in breast cancer.

  1989cited by this paper
• Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report

  1988cited by this paper
• Plasminogen activators, tissue degradation, and cancer.

  1985cited by this paper
• Standardization of steroid receptor analysis in breast cancer biopsies: EORTC receptor group.

  1984cited by this paper
• Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

  1980cited by this paper
• Tumor angiogenesis: therapeutic implications.

  1971cited by this paper

• Making new biomarkers a reality: the case of serum human epididymis protein 4

  2018cites this paper
• The Use of Bayesian Hierarchical Models for Adaptive Randomization in Biomarker-Driven Phase II Studies

  2015cites this paper
• uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies

  2014cites this paper
• Alterations in TP53 gene – Implications in Tumorigenesis Process and Prognosis in Central Nervous System Cancer

  2014cites this paper
• Developing translational research infrastructure and capabilities associated with cancer clinical trials

  2013cites this paper
• A Bayesian Hierarchical Model for Adaptive Biomarker Strategies in Randomized Phase II Studies

  2013cites this paper
• The challenge of gene expression profiling in heterogeneous clinical samples.

  2013cites this paper
• Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group

  2012cites this paper
• Integrating Collection of Biospecimens in Clinical Trials: The Approach of the European Organization for Research and Treatment of Cancer

  2011cites this paper
• From Rous sarcoma virus to plasminogen activator, src oncogene and cancer management

  2011cites this paper
• Emerging biomarkers in breast cancer care.

  2010cites this paper
• Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate‐specific antigen levels of 4–10 ng/mL and disease prognostication after radical prostatectomy

  2010cites this paper
• Insulin-degrading enzyme (IDE) in normal and malignant breast tissues: An immunohistochemical study

  2009cites this paper
• uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial.

  2008cites this paper
• Cancer stem cells: markers or biomarkers?

  2008cites this paper
• Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers

  2008cites this paper
• Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation

  2008cites this paper
• Regulatory Issues in the Co-Development of Oncology Drugs and Proteomic Tests: An Overview

  2008cites this paper
• New Tumor Biomarkers

  2008cites this paper
• 11 Regulatory Aspects of the Oncology Drug Diagnostics Co-Development Process by Proteomics Approach

  2007cites this paper
• Magneto immuno-PCR: a novel immunoassay based on biogenic magnetosome nanoparticles.

  2007cites this paper
• Peptidomics analysis of human blood specimens for biomarker discovery

  2007cites this paper
• Tumor-Associated Proteolytic Factors uPA and PAI-1: Critical Appraisal of Their Clinical Relevance in Breast Cancer and Their Integration into Decision-Support Algorithms

  2007cites this paper
• Oncopeptidomics--a commentary on opportunities and limitations.

  2007cites this paper
• European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers.

  2007cites this paper
• Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations.

  2007cites this paper
• Biomarqueurs pronostiques LOE I/UC+++

  2007cites this paper
• Simultaneous Quantitative Detection of Relevant Biomarkers in Breast Cancer by Quantitative Real-Time PCR

  2006cites this paper
• Antiprotease therapy in cancer: hot or not?

  2006cites this paper
• A new automated flow cytometry data analysis approach for the diagnostic screening of neoplastic B-cell disorders in peripheral blood samples with absolute lymphocytosis

  2006cites this paper
• Prostate cancer: Molecular approaches for detection and prognosis, and angiogenic therapeutic targets

  2006cites this paper
• Evolving Role of Serum Biomarkers in the Management of Ovarian Cancer

  2006cites this paper